Revenue Growth and Margin Expansion
Fourth-quarter revenue was $159 million, up 6% year over year on a reported basis and up 4% organically. Fiscal year 2025 revenue was $594 million, up 4% on a reported basis and up 3% organically. Adjusted EBITDA margin expanded by 310 basis points for the full year.
Record Performance in Multiomics
Multiomics delivered record revenue of $73 million in the quarter, representing 11% growth on a reported basis and 10% organic growth. Sequence volume rose 50% year over year.
Strong Cash Position
The company ended the year with $546 million in cash, cash equivalents, and marketable securities, providing flexibility for growth investment and shareholder returns.
Positive Outlook for Fiscal 2026
Anticipated core revenue growth between 3% to 5% and expected adjusted EBITDA margin expansion of 300 basis points in fiscal 2026, with higher free cash flow generation.